TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01875926

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALX-0171
Description: single dose of 200 mg ALX-0171 via oral inhalation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALX-0171
Description: repeated doses of 200 mg ALX-0171 via oral inhalation once daily for 5 consecutive days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALX-0171
Description: Single dose of 0.3 mg/kg body weight ALX-0171 via intravenous administration
Study: NCT01680328

Intervention type: OTHER
Group type: OTHER
Intervention: 19 injections
Description: Subjects will receive 19 injections in randomised order of which 13 will be in the abdomen and 6 in the thighs. Out of the 19 injections, 2 are needle insertions only. The remaining 17 injections represent different combinations of injection speed and volume of sodium chloride 0.9% solution for injection. The order of the injection speed and volume combinations will be blinded for the subject and the pain will be evaluated by the subject on a VAS (Visual Analogue Scale).

Intervention type: DRUG
Group type: OTHER
Intervention: sodium chloride 0.9% solution
Description: Solution for injection.
Study: NCT02804542

Intervention type: OTHER
Intervention: Observational

Intervention type: OTHER
Intervention: Retrospective review
Study: NCT02007850

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ropivacaine
Description: Patients receive 15 ml of 0.25% ropivacaine pre-operatively through femoral block catheter, followed by 0.2% ropivacaine continuous mode or patient controlled mode for 2 days after surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine
Description: Patients receive 15 ml of 0.25% ropivacaine pre-operatively through femoral block catheter, followed by 0.2% ropivacaine continuous mode or patient controlled mode for 2 days after surgery
Study: NCT00383448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: days -7 through -3: 40 mg/m\^2 intravenously over 2 hours

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total body Irradiation
Description: Administration of TBI: The dose of TBI will be 200 cGy given in a single fraction on day -1. The dose rate will be between 10-19 cGy/minute prescribed to the midplane of the patient at the level of the umbilicus.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: day -2: 140 mg/m\^2 intravenously over 30 minutes

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hematopoietic Stem Cell Transplantation
Description: receives infusion of stem cells on day 0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: 0.3 mg/kg intravenously (IV) days -12 through -8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenylate mofetil
Description: Day -3 through Day 30: 1 gram three times daily (total daily dose 3 grams/day) if the recipient is \>50 kg, or 15 mg/kg three times daily if the recipient is ≤50 kg. The same dosage is used orally or intravenously. Consider dose modification if renal impairment (GFR\<25 mL/minute corrected)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Description: Patients will receive CsA therapy beginning on day -3. Dosing of CsA will be 2.5 mg/kg/dose intravenously (IV); if the recipient body weight is \<40 kg, dosing will be 3 times daily, and if \> 40 kg twice daily. An attempt will be made to maintain a trough cyclosporine level of 250 mg/L to 350 mg/L. Once the patient can tolerate oral medications and has a normal gastrointestinal transit time, CsA will be converted to an oral form at a dose 2.5 x the current IV dose (maximum 12.5 mg/kg/day as initial oral dose).~CsA taper begins at day +100.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: hydroxyurea (HU) beginning day -28 and continuing through alemtuzumab administration
Study: NCT04282200

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: intravenous ketorolac 30 mg every 6 hours
Study: NCT03239171

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cancer ablation
Description: Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cancer ablation
Description: Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Life information rehabilitation therapy
Description: Each treatment: one bottle solution each day, consecutive 3 months, oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Life information rehabilitation therapy
Description: Each treatment: one bottle solution each day, consecutive 3 months, oral administration
Study: NCT02497547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01518127

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intravitreal injection of autologous bone marrow stem cells
Description: intravitreal injection of autologous bone marrow stem cells
Study: NCT05082441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: Exparel mixed with bupivacaine to be infiltrated in the subcutaneous region of the wound instead of plain bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: plain bupivacaine subcutaneous injection as standard of care control
Study: NCT04570410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab IV infusion of 200 mg Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus cisplatin
Description: GC (Gemcitabine plus cisplatin): Gemcitabine 1000mg/m2 D1,D8 iv every 3 weeks Cisplatin70mg/m2,D2,3,4 iv every 3 weeks
Study: NCT03170206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Binimetinib is also an oral drug which stops a signal that a cell receives, instructing it to grow.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6
Study: NCT03502421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Low dose continuous infusion of ketamine 0.3 to 0.5 mg/kg per hour
Study: NCT03220685

Intervention type: BIOLOGICAL
Intervention: Stool analysis
Description: Bacterial extraction in faeces by repeated fractional centrifugation to obtain bacterial mass and DNA sequencing.
Study: NCT03944785

Intervention type: DRUG
Intervention: XADAGO (safinamide)
Description: XADAGO (safinamide) is a monoamine oxidase type B (MAO-B) inhibitor indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing off episodes.
Study: NCT01475656

Intervention type: DRUG
Intervention: levetiracetam
Description: Infants in the both groups will receive 50 mg/kg IV levetiracetam after (continued) seizures are EEG confirmed.

Intervention type: DRUG
Intervention: levetiracetam
Description: Infants in the both groups will receive 50 mg/kg IV levetiracetam after (continued) seizures are EEG confirmed.
Study: NCT02410148

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive ICP measurement (Vittamed 305)
Description: The non-invasive method is based on two-depth TCD technique for simultaneously measuring flow velocities in the intracranial and extracranial segments of the ophthalmic artery (OA).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive ICP measurement (Vittamed 305)
Description: The non-invasive method is based on two-depth TCD technique for simultaneously measuring flow velocities in the intracranial and extracranial segments of the ophthalmic artery (OA).
Study: NCT00830063

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tanezumab 10 mg
Description: tanezumab 10 mg one dose at weeks 0 and 8

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tanezumab 5 mg
Description: tanezumab 5 mg one dose at weeks 0 and 8

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naproxen
Description: naproxen 1000 mg daily for 16 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo to match tanezumab and naproxen dosing
Study: NCT01677559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN8237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN8237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN8237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN8237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN8237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Study: NCT02470338

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MBP plus arthroscopy (Group A)

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: MBP alone (Group B)
Study: NCT00690703

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RF ablation (Rita Medical Systems Model 1500x)
Description: computed tomography-guided RF ablation with an expandable electrode needle
Study: NCT01730937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: By mouth (PO)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: By mouth (PO)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiation therapy
Description: Intensity-modulated radiation therapy (IMRT), stereotactic body radiation therapy (SBRT), and proton therapy are allowed.
Study: NCT03491774

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Montessori Intervention
Description: The Montessori method is a system of teaching developed by Maria Montessori based on principles to promote learning and independence in children. In the context of dementia care, this method has been tried in research settings in older people and was found to be effective in improving certain behavioral outcomes such as eating behaviors, agitation, and mood. The intervention is based on designing and offering activities that take into consideration the interests, needs, past experiences and preferences of participants. Importantly, participants demonstrating positive engagement with the intervention, suggesting that this may be a promising form of support to investigate and develop further for the care of people with dementia.
Study: NCT01129011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PN400 (VIMOVO)
Description: PN400 tablets (Naproxen 500 mg and Esomeprazole 20 mg) twice daily (bid) taken orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Naproxen 500 mg dosed twice daily (bid) orally
Study: NCT02338778

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MV
Description: MV is an intravenous intralipid suspension with 5 various vaccines, including DPT (diphtheria, pertussis, and tetanus ), typhoid, Staphylococcus aureus, paratyphoid A and B. Accessories include microbial A, lecithin, Twain-80, span 20 and soy-bean oil for injection. Inject 0.5 ml of the mixture subcutaneously every week. Best reaction after injection was defined as showing regional red and swollen at the injection point and mild fever and to achieve this, dose increasing or reduction is acceptable.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment
Description: Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Treatment
Description: Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.
Study: NCT00591188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine, interferon-alpha
Description: Patients who meet inclusion/exclusion criteria will receive combination of study drugs.
Study: NCT02633878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese Herbal Medicine plus Oral Micronized Progesterone
Description: Chinese Herbal Medicine (1 pack 2 times a day) + Oral Micronized Progesterone (100 mg three times a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese Herbal Medicine plus Oral Micronized Progesterone Placebo
Description: Chinese Herbal Medicine (1 pack 2 times a day) + Oral Micronized Progesterone Placebo (100 mg three times a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese Herbal Medicine Placebo plus Oral Micronized Progesterone
Description: Chinese Herbal Medicine Placebo (1 pack 2 times a day) + Oral Micronized Progesterone (100 mg three times a day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chinese Herbal Medicine Placebo plus Oral Micronized Progesterone Placebo
Description: Chinese Herbal Medicine Placebo (1 pack 2 times a day) + Oral Micronized Progesterone Placebo (100 mg three times a day)
Study: NCT03761173

Intervention type: DEVICE
Intervention: FlowTriever System
Description: Thrombectomy

Intervention type: DRUG
Intervention: Anticoagulation Agents
Description: Anticoagulation medication
Study: NCT03565445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1948
Description: Intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1948
Description: Intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1948
Description: Intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1948
Description: Intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1948
Description: Intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1948
Description: Intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1948
Description: Intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1948
Description: Intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1948
Description: Intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1948
Description: Intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1948
Description: Intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1948
Description: Intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1948
Description: Intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Intravenously (IV)
Study: NCT03480776

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid
Description: 81 mg PO daily or 325 mg PO daily

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: One tablet PO daily
Study: NCT02504658

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle text messages
Description: Throughout the course of the four-week study, the experimental participants will receive one text message each morning related to general nutrition and exercise goals, and an additional goal status update message on Monday, Wednesday, and Friday evenings. The goal status update message will ask the participants about the status of attaining their nutrition or physical activity goals. Participants may log their progress toward attaining their goals by using the mobile health dashboard feature on BodiMojo.com from a computer or a web-enabled smartphone to indicate their goal status (still working on it or completed it). Participants will be encouraged, via the text messages, to look at information on the BodiMojo program found on the Bodimojo.com website.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control Group
Description: Once participants randomized to the control group have completed the baseline assessment, they will be asked to write down two health goals with the RA. The same goals will be suggested for this group as for the Intervention group (see Appendix). They will take home a copy of the goals they have set. The participants will be also given a 16-page pamphlet from NIDDK A Guide for Teenagers: Take Charge of Your Health! to take home to read over.
Study: NCT02465593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP503
Description: The volume of PEP503 to be administered is based on the baseline tumor volume of each patient. There will be 4 dose levels in Phase Ib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 225 mg/m2 a day, 5 days/week for 5 weeks during radiotherapy period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: 825 mg/m2 BID 5 days/week for 5 weeks during the radiotherapy period

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical resection
Description: Approximately 8 weeks after the completion of chemoradiotherapy, surgical resection of the tumor (total mesorectal excision, TME) will be performed once the tumor become resectable.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Intensity-modulated radiation therapy (IMRT) or intensity modulated arc therapy (IMAT) of 5,000 cGy in 25 fractions (200 cGy/fraction, 5 times/week) to gross tumor and involved nodes and 4,500 cGy in 25 fractions (180 cGy/fraction, 5 times/week) to pelvis, starting at 24 hours after PEP503 injection.
Study: NCT03009526

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfadoxine-pyrimethamine
Description: 500 mg sulfadoxine and 25 mg pyrimethamine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dihydroartemisinin-piperaquine
Description: 40 mg dihydroartemisinin and 320 mg piperaquine
Study: NCT02718053

Intervention type: OTHER
Intervention: L-stiff
Description: spasticity measurement with Lokomat

Intervention type: OTHER
Intervention: L-stiff
Description: spasticity measurement with Lokomat

Intervention type: OTHER
Intervention: Ashworth
Description: spasticity measurement with Ashworth scale

Intervention type: OTHER
Intervention: Ashworth
Description: spasticity measurement with Ashworth scale
Study: NCT01343147

Intervention type: OTHER
Group type: OTHER
Intervention: Microwave diathermy
Description: Deep tissue heating via microwave diathermy

Intervention type: OTHER
Group type: OTHER
Intervention: Superficial hyperthermia
Description: Superficial heating via hot pack application
Study: NCT02395588

Intervention type: OTHER
Intervention: Guideline based care
Description: Patient education using guideline based teaching guides
Study: NCT04011995

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent caloric restriction
Description: The intervention is based on the 5:2 diet, which involves caloric restriction for 2 days (consecutive or nonconsecutive, 600kcal/d for male and 500kcal/d for female) per week and unrestricted eating during the other 5 days of the week.~Total trial duration is one month consisting of a 14-day intervention phase and a 14-day self-maintenance phase. During the maintenance phase, two follow-up electronic questionnaires were conducted.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low carbohydrate diet
Description: During the 14-day intervention period, the subjects receive 7 days (consecutive or nonconsecutive) of low carbohydrate diet intervention. Carbohydrate intake of low-carbohydrate diet should be controlled as ≤ 50g per day.~Total trial duration is one month consisting of a 14-day intervention phase and a 14-day self-maintenance phase. During the maintenance phase, two follow-up electronic questionnaires were conducted.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health education on reducing the cardiometabolic risk
Description: Health education is conducted once a week during 14-day dietary intervention for all subjects. Health education including the understanding of cardiovascular disease, how to determine the cardiometabolic risk level, and the lifestyle intervention as caloric restriction and increased physical activity to promote health.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health education on reducing the cardiometabolic risk
Description: Health education is conducted once a week during 14-day dietary intervention for all subjects. Health education including the understanding of cardiovascular disease, how to determine the cardiometabolic risk level, and the lifestyle intervention as caloric restriction and increased physical activity to promote health.
Study: NCT03043950

Intervention type: DRUG
Intervention: Panitumumab
Description: Patients will be scheduled to receive first line therapy with the combination of Panitumumab (6 mg / kg i.v, given once every two weeks) and FOLFIRI or FOLFOX, according to current SmPC.

Intervention type: DRUG
Intervention: Panitumumab
Description: Patients will be scheduled to receive first line therapy with the combination of Panitumumab (6 mg / kg i.v, given once every two weeks) and FOLFIRI or FOLFOX, according to current SmPC.

Intervention type: DRUG
Intervention: Panitumumab
Description: Patients will be scheduled to receive first line therapy with the combination of Panitumumab (6 mg / kg i.v, given once every two weeks) and FOLFIRI or FOLFOX, according to current SmPC.